Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 7:12 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1225–1248 of 1,551 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Ulcerative Clear all

Conditions: Ulcerative Colitis
Interventions: MMX Mesalamine; Drug
Lead sponsor: Shire; Industry
Eligibility: 18 Years and older
Enrollment: 290 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 62
States / cities: Birmingham, Alabama • Jonesboro, Arkansas • Long Beach, California + 53 more

Conditions: Crohn's Disease, Ulcerative Colitis, Clostridium Difficile, Inflammatory Bowel Disease
Interventions: Blood and stool sample; Other
Lead sponsor: Boston Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Ulcerative Colitis, Protein Metabolism, Energy Expenditure
Interventions: Stable amino acid isotopes; Other
Lead sponsor: Indiana University; Other
Eligibility: 6 Years to 18 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Wounds, Leg Ulcers, Pressure Ulcers, Diabetic Foot Ulcers
Interventions: AutoloGel System; Device
Lead sponsor: Cytomedix; Industry
Eligibility: 18 Years to 95 Years
Enrollment: 131 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2012
U.S. locations: 2
States / cities: Augusta, Georgia • El Paso, Texas

Conditions: Venous Leg Ulcers
Interventions: Aurix; Device
Lead sponsor: Cytomedix; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Boise, Idaho

Conditions: Ulcerative Colitis
Interventions: RO7837195, RO7837195 Matched Placebo; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 224 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 9
States / cities: Lancaster, California • San Diego, California • Colorado Springs, Colorado + 6 more

Conditions: Pressure Ulcer, Pressure Injury, Falls Injury
Interventions: Masimo Centroid System; Device
Lead sponsor: Masimo Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Diabetic Foot Ulcers (DFU), Foot Ulcer Chronic, Ulcer, Diabetic Foot Ulcer
Interventions: Blue Drop Foot Scanner; Other
Lead sponsor: Applied Biologics, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Clinton Township, Michigan

Conditions: Ulcerative Colitis
Interventions: KB295; Other
Lead sponsor: Kaleido Biosciences; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 2
States / cities: Chicago, Illinois • Austin, Texas

Conditions: Colitis, Ulcerative
Interventions: Anrukinzumab, placebo; Biological · Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 48
States / cities: Birmingham, Alabama • Phoenix, Arizona • Anaheim, California + 19 more

Conditions: Ulcerative Colitis
Interventions: Not listed
Lead sponsor: Janssen Biotech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 535 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2027
U.S. locations: 16
States / cities: Murrieta, California • Rialto, California • Ventura, California + 13 more

Conditions: Behcet Syndrome, Behcet Disease
Interventions: Topical Pentoxifylline Gel (Vehicle +PTX), Topical Placebo Gel (Vehicle); Drug
Lead sponsor: Silk Road Therapies, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis, Indeterminate Colitis, Functional Abdominal Pain Syndrome, Functional Bowel Disorder, Esophageal Diseases, Gastroduodenal Disorder, Bowel Dysfunction, Gallbladder Diseases, Sphincter of Oddi Dysfunction, Anorectal Disorder
Interventions: Esophagogastroduodenoscopy (EGD) with biopsy, Colonoscopy w/ biopsy; Diagnostic Test
Lead sponsor: Seattle Children's Hospital; Other
Eligibility: 6 Years to 21 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Ulcerative Colitis, Ulcerative Colitis Acute, Ulcerative, Ulcerative Colitis Flare
Interventions: PL8177 Placebo, PL8177; Drug
Lead sponsor: Palatin Technologies, Inc; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 14
States / cities: Tucson, Arizona • Lancaster, California • Tarzana, California + 11 more

Conditions: Inflammatory Bowel Diseases, Ulcerative Colitis, Crohn Disease
Interventions: Morning light treatment, Treatment-as-usual; Device · Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Ulcerative Colitis
Interventions: Catered diet, Diet guidance sessions, Dietary counseling, Feedback sessions; Behavioral
Lead sponsor: University of Miami; Other
Eligibility: 16 Years to 75 Years
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Proctitis, Proctosigmoiditis
Interventions: Budesonide Foam; Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 114 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Colitis, Ulcerative
Interventions: LY3471851, Placebo; Drug
Lead sponsor: Nektar Therapeutics; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 7
States / cities: Litchfield Park, Arizona • Kissimmee, Florida • Pensacola, Florida + 4 more

Conditions: Inflammatory Bowel Disease
Interventions: Not listed
Lead sponsor: Johns Hopkins University; Other
Eligibility: 5 Years and older
Enrollment: 2,400 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Corneal Ulcer
Interventions: Mesenchymal Stromal Cells, Control Solution; Biological · Other
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 4
States / cities: Chicago, Illinois • Baltimore, Maryland • Boston, Massachusetts + 1 more

Conditions: Pouchitis, Ulcerative Colitis
Interventions: Observational, No intervention; Other
Lead sponsor: Alimentiv Inc.; Other
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 2
States / cities: New York, New York • Cleveland, Ohio

Conditions: Pyoderma Gangrenosum, Skin Diseases, Wound Heal, Pyoderma, Skin Ulcer
Interventions: Guselkumab; Drug
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years to 99 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: Columbus, Ohio • Portland, Oregon

Conditions: Diabetic Foot Ulcer
Interventions: InnovaMatrix AC porcine placental ECM therapy; Device
Lead sponsor: ConvaTec Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 5
States / cities: North Port, Florida • Buffalo, New York • Monroeville, Pennsylvania + 2 more

Conditions: Thoracic Aortic Aneurysm
Interventions: TEVAR, Non-TEVAR medical treatment; Other
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years to 99 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Search by objective public record fields.

Strategies in Maintenance for Patients Receiving Long-term Therapy (S.I.M.P.L.E.) With MMX (Multi-Matrix System) Mesalamine for Ulcerative Colitis (UC)

Host Immune Response to Clostridium Difficile Infection in Inflammatory Bowel Disease Patients

Metabolic Response to Infliximab in Pediatric Ulcerative Colitis

The AutoloGel™ Post-Market Surveillance (TAPS) Program

Effectiveness of Aurix Therapy in Venous Leg Ulcers

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC)

Usability Validation of Patient Monitoring Device for Pressure Injury Prevention and Fall Detection

Evaluating the Durability of Closure for Diabetic Foot Ulcers Following a Randomized, Controlled, Modified Platform Trial.

A Clinical Study to Assess the Effects of KB295 in Patients With Ulcerative Colitis (UC) on Gut Microbiota Structure and Function

Pharmacokinetics/Pharmacodynamics Biomarker Study in Active Ulcerative Colitis Patients

An Observational Prospective Long-term Exposure Registry of Adult Patients With Moderate-to-Severe Ulcerative Colitis

Topical Pentoxifylline Gel on Behcet's Disease Genital Ulcers

Seattle Spatial Transcriptomic Research in Inflammatory Bowel Disease Evaluation (STRIDE)

Phase 2a to Evaluate PL-8177 in Subjects with Active Ulcerative Colitis (UC)

IBD-Sleep: A Pilot Study Looking at Changes in Sleep Timing and IBD Symptoms

Tailored Anti-Inflammatory (A-I) Diet for Americans With Ulcerative Colitis (UC)

The Safety and Tolerability of Budesonide Foam in Participants With Active Ulcerative Proctitis or Proctosigmoiditis

A Study of LY3471851 in Adult Participants With Moderately to Severely Active Ulcerative Colitis (UC)

Multi-Center African-American Inflammatory Bowel Disease Study (MAAIS)

Efficacy of Locally Delivered Allogeneic Mesenchymal Stromal Cells

Assessment of Patients With Acute Pouchitis Treated With Antibiotics

Guselkumab in the Treatment of Adults With Pyoderma Gangrenosum (PG)

Sterilised, Porcine Placental Tissue in the Treatment of Chronic Diabetic Foot Ulcers

The CardiOvascular Remodeling Following Endovascular Aortic Repair (CORE) Study